---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-109521"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2024-10-17T23:59:59+00:00"
generated_at: "2026-05-30T13:00:26.176035+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting

## Summary
- CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.
- Options granted under 2018 Equity Incentive Plan; exercisable in full as of Oct 16, 2024 regardless of vesting.
- New exercise price set to $0.0001, the closing OTC price on the repricing date.
- Option repricing approved by Board on Oct 16, 2024; amendment approved by Compensation Committee.

## SEC filing metadata
- accession: 0001104659-24-109521
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2024-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465924109521/0001104659-24-109521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465924109521/tm2426349d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-109521
- JSON: https://secwatch.observer/filing/0001104659-24-109521.json
- Plain text: https://secwatch.observer/filing/0001104659-24-109521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.